药物更新：最近的药物批准，2025年夏季版。

IF 0.9 Q4 NURSING

NURSE PRACTITIONER Pub Date : 2025-08-01 Epub Date: 2025-07-29 DOI:10.1097/01.NPR.0000000000000344

Adriane B Marino, Evan S Drake, Jenna D Theroux, Ryan Osteen, Rebecca Sarpong, Ashlyn Hughes, Janna Plummer

{"title":"药物更新：最近的药物批准，2025年夏季版。","authors":"Adriane B Marino, Evan S Drake, Jenna D Theroux, Ryan Osteen, Rebecca Sarpong, Ashlyn Hughes, Janna Plummer","doi":"10.1097/01.NPR.0000000000000344","DOIUrl":null,"url":null,"abstract":"Abstract: In the final half of 2024, the US FDA approved several new drugs that have relevance for those practicing in primary care. This article highlights the following new medications: donanemab-azbt (Kisunla), nalmefene injection (Zurnai), epinephrine nasal spray (neffy), palopegteriparatide (Yorvipath), xanomeline and trospium chloride (Cobenfy), and sulopenem etzadroxil/probenecid (Orlynvah). Additionally, this article highlights the recent approval of obstructive sleep apnea as a new indication for tirzepatide (Zepbound) and chronic obstructive pulmonary disease as a new indication for dupilumab (Dupixent).","PeriodicalId":51812,"journal":{"name":"NURSE PRACTITIONER","volume":"50 8","pages":"10-24"},"PeriodicalIF":0.9000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Drug Update: Recent drug approvals, summer 2025 edition.\",\"authors\":\"Adriane B Marino, Evan S Drake, Jenna D Theroux, Ryan Osteen, Rebecca Sarpong, Ashlyn Hughes, Janna Plummer\",\"doi\":\"10.1097/01.NPR.0000000000000344\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract: In the final half of 2024, the US FDA approved several new drugs that have relevance for those practicing in primary care. This article highlights the following new medications: donanemab-azbt (Kisunla), nalmefene injection (Zurnai), epinephrine nasal spray (neffy), palopegteriparatide (Yorvipath), xanomeline and trospium chloride (Cobenfy), and sulopenem etzadroxil/probenecid (Orlynvah). Additionally, this article highlights the recent approval of obstructive sleep apnea as a new indication for tirzepatide (Zepbound) and chronic obstructive pulmonary disease as a new indication for dupilumab (Dupixent).\",\"PeriodicalId\":51812,\"journal\":{\"name\":\"NURSE PRACTITIONER\",\"volume\":\"50 8\",\"pages\":\"10-24\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NURSE PRACTITIONER\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.NPR.0000000000000344\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"NURSING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NURSE PRACTITIONER","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.NPR.0000000000000344","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"NURSING","Score":null,"Total":0}

引用次数: 0

摘要

摘要：2024年下半年，美国FDA批准了几种与初级保健相关的新药。本文重点介绍了以下新药物：donanemabb -azbt （Kisunla）、纳美芬注射剂（Zurnai）、肾上腺素鼻喷雾剂（neffy）、palopegteriparatide （Yorvipath）、xanomeline和trospium chloride （Cobenfy）和sulopenem etzadroxil/probenecid （Orlynvah）。此外，这篇文章强调了最近批准阻塞性睡眠呼吸暂停作为替西帕肽（Zepbound）的新适应症和慢性阻塞性肺疾病作为杜匹单抗（Dupixent）的新适应症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Drug Update: Recent drug approvals, summer 2025 edition.

Abstract: In the final half of 2024, the US FDA approved several new drugs that have relevance for those practicing in primary care. This article highlights the following new medications: donanemab-azbt (Kisunla), nalmefene injection (Zurnai), epinephrine nasal spray (neffy), palopegteriparatide (Yorvipath), xanomeline and trospium chloride (Cobenfy), and sulopenem etzadroxil/probenecid (Orlynvah). Additionally, this article highlights the recent approval of obstructive sleep apnea as a new indication for tirzepatide (Zepbound) and chronic obstructive pulmonary disease as a new indication for dupilumab (Dupixent).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

NURSE PRACTITIONER NURSING-

CiteScore

0.90

自引率

0.00%

发文量

183

期刊介绍： With a circulation of 20,000, The Nurse Practitioner is the leading monthly source for clinical, practical, cutting-edge information for advanced practice nurses and other primary care clinicians. Each issue presents peer-reviewed articles that range from clinical topics and research to political and practice issues. In addition, The Nurse Practitioner provides regular features, columns, continuing education, staff development education, and more.